Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incomplete tumor resection, central neuroradiological review, and second surgery in pediatric patients with intracranial ependymoma treated in the E-HIT2000 trial.

Journal of neurosurgery. Pediatrics·2026
Same author

The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy.

Frontiers in bioengineering and biotechnology·2026
Same author

Novel bispecific T-cell engagers overcoming acquired EGFR resistance.

mAbs·2026
Same author

Neuropsychological late effects in young children with medulloblastoma: A longitudinal analysis after 5 and 15 years from the HIT-SKK-'87/'92 studies.

Neuro-oncology practice·2026
Same author

The HIT Network for Children and Adolescents With CNS Tumors Facilitates Improvements of Diagnostic Assessments, Multimodal Treatments, Individual Counseling, and Research in Germany, Austria, and Switzerland.

Pediatric blood & cancer·2026
Same author

Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19.

Clinical therapeutics·2026

Related Experiment Video

Updated: Jun 27, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

Targeted therapeutic RNases (ImmunoRNases).

Thomas Schirrmann1, Jürgen Krauss, Michaela A E Arndt

  • 1Technische Universität Braunschweig, Braunschweig, Germany. th.schirrmann@tu-bs.de

Expert Opinion on Biological Therapy
|December 10, 2008
PubMed
Summary

Ribonucleases are promising anticancer therapeutics, offering potent cell-killing activity without significant immunogenicity. Targeted immuno-ribonucleases (ImmunoRNases) show potential for enhanced tumor cell targeting and improved cancer treatment outcomes.

More Related Videos

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
10:44

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

Published on: May 5, 2023

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Related Experiment Videos

Last Updated: Jun 27, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
10:44

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

Published on: May 5, 2023

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Traditional immunotoxins face limitations due to immunogenicity and non-specific toxicity.
  • Ribonucleases (RNases) from the RNase A superfamily exhibit potent antineoplastic activity upon cell internalization.
  • RNases possess low immunogenicity and non-specific toxicity, making them suitable for therapeutic development.

Purpose of the Study:

  • To review the therapeutic potential of targeted ribonucleases, also known as ImmunoRNases.
  • To highlight ImmunoRNases as a novel approach for anticancer therapeutics.
  • To discuss the advantages of RNases over traditional immunotoxins.

Main Methods:

  • Review of existing literature on RNase-based therapeutics and immunotoxins.
  • Analysis of the properties of RNase A superfamily members, including Onconase.
  • Exploration of conjugation and fusion strategies for creating targeted ImmunoRNases.

Main Results:

  • Onconase (ONC), a frog-derived RNase, is the first and only RNase currently in clinical trials for cancer therapy.
  • Conjugation or fusion of RNases to tumor-specific antibodies enhances tumor cell killing.
  • ImmunoRNases demonstrate potent antineoplastic activity with reduced immunogenicity and toxicity.

Conclusions:

  • Targeted ImmunoRNases represent a promising novel class of anticancer therapeutics.
  • RNase-based strategies offer a viable alternative to conventional immunotoxins.
  • Further development of ImmunoRNases holds significant potential for improving cancer treatment.